Hard to Treat Diseases, Inc. (HTDS) Finalizes Agreement with Yunnan Walvax Biotech
Under the terms of the agreement Mellow Hope will be fully authorized to do the International marketing of Haemophilus influenza type “B” conjugate vaccine in the global market. Safe Harbor Statement Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements … Read Full Press Release